智飞生物：带状疱疹mRNA疫苗临床试验申请获受理

Core Viewpoint - The company, Zhifei Biological Products, has received a clinical trial application acceptance notice for its mRNA vaccine for shingles from the National Medical Products Administration, allowing it to proceed with clinical trials if no objections are raised within 60 days [1] Group 1 - Zhifei Biological's wholly-owned subsidiary, Zhifei Longkema, is responsible for the development of the shingles mRNA vaccine [1] - The acceptance notice has the application number CXSL2500961 [1] - The company can initiate clinical trials as long as it does not receive any negative or questioning feedback from the drug review center within 60 days from the acceptance date [1]